Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.47 |
| ▸ | S1PR2 | O95136 | 4/20 | 0.45 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.38 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2531711 | 0.92 | DRD2 (0.43) | DRD2S1PR2DRD4DRD3MEN1 | |
| SCHEMBL3387449 | 0.89 | S1PR2 (0.43) | DRD2S1PR2DRD4DRD3CYP3A4 | |
| SCHEMBL2534239 | 0.85 | DRD2 (0.38) | DRD2S1PR2DRD4DRD3FFAR4 | |
| SCHEMBL3346703 | 0.84 | DRD2 (0.36) | DRD2S1PR2DRD4DRD3EPHX2 | |
| SCHEMBL3346698 | 0.84 | DRD2 (0.36) | DRD2S1PR2DRD4DRD3EPHX2 | |
| SCHEMBL23365187 | 0.84 | S1PR2 (0.40) | DRD2S1PR2DRD4DRD3MEN1 | |
| SCHEMBL5378448 | 0.82 | S1PR2 (0.39) | DRD2S1PR2DRD4DRD3FFAR4 | |
| SCHEMBL3385458 | 0.80 | MEN1 (0.43) | DRD2S1PR2MEN1KMT2ACYP3A4 | |
| SCHEMBL3125858 | 0.80 | DRD2 (0.41) | DRD2DRD4DRD3MEN1KMT2A | |
| SCHEMBL2535627 | 0.80 | S1PR2 (0.39) | DRD2S1PR2DRD4DRD3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1714961-B1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-09 | — | — | EP | claimed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | claimed |
| EP-1714961-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2006-10-25 | — | — | EP | claimed |
| EP-1714961-B1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-09 | — | — | EP | disclosed |
| EP-1963268-B1 | DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2010-12-01 | — | — | EP | disclosed |
| US-20080269286-A1 | Disubstituted Phenylpiperidines as Modulators of Cortical Catecholaminergic Neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2008-10-30 | — | — | US | disclosed |
| EP-1963268-A1 | DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | Neurosearch Sweden AB (SE) | 2008-09-03 | — | — | EP | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| WO-2007065655-A1 | DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NEUROSEARCH SWEDEN AB (SE) | 2007-06-14 | — | — | WO | disclosed |
| EP-1714961-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2006-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | CYP3A5, CYP3A43, TP53 | DRD2 3805/4885S1PR2 4307/4885DRD4 4276/4885 |
| US-20080269286-A1 | Disubstituted Phenylpiperidines as Modulators of Cortical Catecholaminergic Neurotransmission | SLC6A2, SLC18A2, PNMT | DRD2 27/4885S1PR2 537/4885DRD4 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.